| 翻訳と辞書 |
| dapagliflozin ： ウィキペディア英語版 |
dapagliflozin
Dapagliflozin (INN/USAN,〔(Statement on a nonproprietory name adopted by the USAN council )〕 trade name Farxiga in the US and Forxiga in the EU) is a drug of the gliflozin class, used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.
==Medical uses==
In July 2011 a US Food and Drug Administration (FDA) committee recommended against approval until more data were available.
The FDA approved dapagliflozin on January 8, 2014 for glycemic control, along with diet and exercise, in adults with type 2 diabetes. The FDA approved the combination product dapagliflozin and metformin hydrochloride extended-release, called Xigduo XR, in October 2014.
In April 2012, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion on the drug. It is now marketed in a number of European countries.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「dapagliflozin」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|